**Supplementary Table 1: Baseline demographics and clinical characteristics.**

|  |  |
| --- | --- |
| **Variables** | **Patients, *n* (%) or mean ±** **SD** |
| GenderMale, *n* (%)Female, *n* (%)Age (years), mean ± SDAge of onset (years), mean ± SDDisease duration, mean ± SDPASI baseline scores, mean ± SDBSA (%), mean ± SDBMI (kg/m2)Comorbidities, *n* (%)HypertensionDyslipidemia,DiabetesPsoriasis with scalp involvementIGA mod 2011 score, *n* (%)234SmokeDrinkPrevious biological therapy, *n* (%)AdalimumabSecukinumabUstekinumabDLQI, mean ± SD |

|  |
| --- |
| 45 (72.6) |
| 17 (27.4) |
| 38.1 ± 15.3 |
| 27.9 ± 13.9 |
| 10.5 ± 10.215.8 ± 9.528.0 ± 18.1 |
| 23.6 ± 3.4 |

|  |
| --- |
| 13 (21.0) |
| 11 (17.7) |
| 6 (9.7) |
| 13 (21.0) |
|  |
| 2 (3.2) |
|  50 (80.6) |
|  10 (16.1) |

22 (35.5)30 (48.4)2 (3.2)3 (4.8)1 (1.6)18.7 ± 7.9 |

BMI: Body mass index; BSA: Body surface area; DLQI: Dermatology life quality index; IGA mod 2011: Investigator's global assessment, 2011, modified (version scores range from 0 [clear skin] to 4 [severe disease]); PASI: Psoriasis area and severity index; SD: Standard deviation.